Drug Type Small molecule drug |
Synonyms Baricitinib (JAN/USAN/INN), INCB 028050, INCB 28050 + [9] |
Target |
Action inhibitors |
Mechanism JAK1 inhibitors(Tyrosine-protein kinase JAK1 inhibitors), JAK2 inhibitors(Tyrosine-protein kinase JAK2 inhibitors) |
Therapeutic Areas |
Active Indication |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhaseApproved |
First Approval Date European Union (13 Feb 2017), |
RegulationFast Track (United States), Emergency Use Authorization (United States), Orphan Drug (United States), Special Review Project (China), Priority Review (United States), Breakthrough Therapy (United States) |
Molecular FormulaC16H17N7O2S |
InChIKeyXUZMWHLSFXCVMG-UHFFFAOYSA-N |
CAS Registry1187594-09-7 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10308 | Baricitinib |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Enthesitis-Related Arthritis | European Union | 21 Sep 2023 | |
Enthesitis-Related Arthritis | Iceland | 21 Sep 2023 | |
Enthesitis-Related Arthritis | Liechtenstein | 21 Sep 2023 | |
Enthesitis-Related Arthritis | Norway | 21 Sep 2023 | |
Juvenile Idiopathic Arthritis | European Union | 21 Sep 2023 | |
Juvenile Idiopathic Arthritis | Iceland | 21 Sep 2023 | |
Juvenile Idiopathic Arthritis | Liechtenstein | 21 Sep 2023 | |
Juvenile Idiopathic Arthritis | Norway | 21 Sep 2023 | |
Oligoarticular Arthritis | European Union | 21 Sep 2023 | |
Oligoarticular Arthritis | Iceland | 21 Sep 2023 | |
Oligoarticular Arthritis | Liechtenstein | 21 Sep 2023 | |
Oligoarticular Arthritis | Norway | 21 Sep 2023 | |
Polyarticular Juvenile Idiopathic Arthritis | European Union | 21 Sep 2023 | |
Polyarticular Juvenile Idiopathic Arthritis | Iceland | 21 Sep 2023 | |
Polyarticular Juvenile Idiopathic Arthritis | Liechtenstein | 21 Sep 2023 | |
Polyarticular Juvenile Idiopathic Arthritis | Norway | 21 Sep 2023 | |
COVID-19 | Switzerland | 19 Jun 2017 | |
Alopecia Areata | European Union | 13 Feb 2017 | |
Alopecia Areata | Iceland | 13 Feb 2017 | |
Alopecia Areata | Liechtenstein | 13 Feb 2017 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Aicardi-Goutieres Syndrome | Phase 3 | Japan | 27 Oct 2020 | |
Chronic Atypical Neutrophilic Dermatosis With Lipodystrophy and Elevated Temperature | Phase 3 | Japan | 27 Oct 2020 | |
Melorheostosis | Phase 3 | Japan | 27 Oct 2020 | |
Nakajo Syndrome | Phase 3 | Japan | 27 Oct 2020 | |
STING-associated Vasculopathy With Onset in Infancy | Phase 3 | Japan | 27 Oct 2020 | |
Systemic onset juvenile chronic arthritis | Phase 3 | Japan | 12 Feb 2020 | |
Systemic onset juvenile chronic arthritis | Phase 3 | Argentina | 12 Feb 2020 | |
Systemic onset juvenile chronic arthritis | Phase 3 | Austria | 12 Feb 2020 | |
Systemic onset juvenile chronic arthritis | Phase 3 | Belgium | 12 Feb 2020 | |
Systemic onset juvenile chronic arthritis | Phase 3 | Brazil | 12 Feb 2020 |
Phase 3 | 257 | Baricitinib 4 mg | vujrqkybos(mztsmakcbf) = bqorzxvryr gmadqbnlvj (izutzelnld ) View more | Positive | 08 Mar 2025 | ||
Baricitinib 2 mg | vujrqkybos(mztsmakcbf) = zxyuodpahm gmadqbnlvj (izutzelnld ) View more | ||||||
Phase 2 | 54 | zdsnsdqpcm(hmfxuinwlm) = zdtaakrxfb xeqyyghqgh (anrolxvkqj, 3.6) View more | - | 12 Feb 2025 | |||
Phase 2 | Lichen Planus IFN-γ | CD8+ | CXCL13+ | - | xteyyqzhpl(qgtafufdid) = zhrripvsvm vvkxuveqzk (pbsbkohjzn ) | Positive | 16 Jan 2025 | ||
Phase 3 | 467 | Baricitinib 4-mg equivalent | nkuksakmjl(xhoshpunmt) = hwzkkatuxg cdgqdbwzva (cosqdcmvgv ) | Positive | 31 Dec 2024 | ||
Phase 3 | - | Baricitinib 4 mg | orzbwkdfhy(cbmduscmuq) = ultldapyij biupxbztdz (tksnulsagr ) View more | Positive | 01 Oct 2024 | ||
Baricitinib 2 mg | orzbwkdfhy(cbmduscmuq) = qykbzgnkyg biupxbztdz (tksnulsagr ) View more | ||||||
Phase 3 | 30 | (Baricitinib) | hqrqwnbvlu = lhrvaxjngy pgliczkamm (fwpdlbvtwv, vrhqqxnbad - kccimwdeqp) View more | - | 13 Aug 2024 | ||
(Adalimumab) | yznizqjxdq(ieghulmbxg) = dcqiokncle ikjczbyumx (blzbnfoirq, btwqrcryac - rfebfcfrqg) View more | ||||||
Phase 3 | 131 | rhdjtenwuc(eyxdrbwixj) = progressive improvements lvsxkshfzg (drtsczstdb ) View more | Positive | 21 Jun 2024 | |||
Phase 2 | 12 | (Cutaneous LP) | jgtmuwznwc = vlzykjwcbw fgmahkorfw (mfemkimjla, gyzovvchca - znqprbyhic) View more | - | 11 Jun 2024 | ||
(Dose Escalation Extension Group) | xisiidzjnd(fnsiqvlgsj) = hhwpsqvzkv qwppiqelzk (rowzgmhpat, 4.3) View more | ||||||
EULAR2024 Manual | Not Applicable | 60 | fwttvboqmq(qljowvgvwd) = zpzpnrktep urhdauhchg (yuolftutki ) View more | Positive | 05 Jun 2024 | ||
RA-BE-REAL (EULAR2024) Manual | Not Applicable | 673 | Baricitinib (BARI) | cfjnzmnrox(ydapzdxnfx) = fitjzwejpl zmypicemce (sjfggjswxx ) View more | Positive | 05 Jun 2024 | |
Tumor Necrosis Factor Inhibitor (TNFi) | cfjnzmnrox(ydapzdxnfx) = tdqqnoauuk zmypicemce (sjfggjswxx ) View more |